T1	Participants 167 241	Two hundred and twelve patients treated for prostatic cancer grade I or II
T2	Participants 294 494	The patients were part of a multicentre study in the Stockholm area and had been randomized to treatment with either estramustine phosphate (Estracyt) or polyestradiol phosphate and ethinyl estradiol.
